title: The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
abstract: BACKGROUND
  The purpose of this study was to assess the efficacy and safety between tenofovir and entecavir in the treatment of CHB and HBV related cirrhosis through Meta-analysis. Methods The electronic databases of PubMed, the Cochrane Library, Nature, CNKI and WanFang data were searched. The key words were: ("tenofovir", "entecavir") and ("Chronic Hepatitis B" or "CHB") and "Liver cirrhosis". Heterogeneity and report bias were analyzed.
  
  
  RESULTS
  There was significant difference of ALT norm level in the short-term period of 3months (RR=1.43, 95%CI: 1.06-1.94, P<0.017) and 6months (RR=0.89, 95%CI: 0.81-0.97, P<0.017), and significant difference of undetectable HBV-DNA only in 3months follow-up period (RR=1.59, 95%CI: 1.04-2.42, P<0.017) between TDF and ETV, but no significant difference in the long-term period. There is significant difference between TDF and ETV in eGFR level (RR=1.601, 95%CI: 1.035-2.478, P=0.0034) and hypophosphatemia incidence (RR=4.008, 95%CI: 1.485-10.820, P=0.006).
  
  
  CONCLUSIONS
  TDF has a better efficacy than ETV in 3months treatment duration, but intriguingly, TDF might not better than ETV during the 6months treatment period in the viral suppression and liver function improvement. There's no significant difference between TDF and ETV in the long-term treatment duration and in the treatment of HBV related liver cirrhosis. Both TDF and ETV could influence renal function but patients under TDF therapy may have more risk to suffer from renal damage and hypophosphatemia.
authors.affiliation: Department of Gastroenterology and Hepatology, Beijing You'an Hospital affiliated with Capital Medical University, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Han
authors.affiliation: Department of Gastroenterology and Hepatology, Beijing You'an Hospital affiliated with Capital Medical University, China.
authors.forename: Ajuan
authors.initials: A
authors.lastname: Zeng
authors.affiliation: Department of Gastroenterology and Hepatology, Beijing You'an Hospital affiliated with Capital Medical University, China.
authors.forename: Huiyu
authors.initials: H
authors.lastname: Liao
authors.affiliation: Department of Gastroenterology and Hepatology, Beijing You'an Hospital affiliated with Capital Medical University, China.
authors.forename: Yanmin
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Gastroenterology and Hepatology, Beijing You'an Hospital affiliated with Capital Medical University, China.
authors.forename: Yuhan
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Gastroenterology and Hepatology, Beijing You'an Hospital affiliated with Capital Medical University, China. Electronic address: huiguoding@126.com.
authors.forename: Huiguo
authors.initials: H
authors.lastname: Ding
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000517:prevention & control; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D017674:Hypophosphatemia / Q000209:etiology / Q000517:prevention & control; D008103:Liver Cirrhosis; D000068698:Tenofovir / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects*
chemical_list: C413685:entecavir; D006147:Guanine; D000068698:Tenofovir
keywords: CHB; Chronic hepatitis B; Efficacy; Entecavir; HBV; Safety; Tenofovir